Avaglim

RSS

Withdrawn

This medicine's authorisation has been withdrawn

rosiglitazone / glimepiride
MedicineHumanWithdrawn

Dutch is available via eTranslation, the European Commission's machine translation service.

Translate to Dutch | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

The marketing authorisation for Avaglim has been withdrawn for safety reasons following a decision by the European Commission.

български (BG) (676.95 kB - PDF)

Bekijk

español (ES) (574.56 kB - PDF)

Bekijk

čeština (CS) (639.66 kB - PDF)

Bekijk

dansk (DA) (577.22 kB - PDF)

Bekijk

Deutsch (DE) (580.29 kB - PDF)

Bekijk

eesti (ET) (575.67 kB - PDF)

Bekijk

ελληνικά (EL) (688.24 kB - PDF)

Bekijk

français (FR) (578.92 kB - PDF)

Bekijk

italiano (IT) (579.68 kB - PDF)

Bekijk

latviešu (LV) (646.64 kB - PDF)

Bekijk

lietuvių (LT) (606.52 kB - PDF)

Bekijk

magyar (HU) (629.47 kB - PDF)

Bekijk

Malti (MT) (577.48 kB - PDF)

Bekijk

Nederlands (NL) (574.86 kB - PDF)

Bekijk

polski (PL) (639.54 kB - PDF)

Bekijk

português (PT) (574.95 kB - PDF)

Bekijk

română (RO) (607.15 kB - PDF)

Bekijk

slovenčina (SK) (635.29 kB - PDF)

Bekijk

slovenščina (SL) (630.33 kB - PDF)

Bekijk

suomi (FI) (576.98 kB - PDF)

Bekijk

svenska (SV) (575.64 kB - PDF)

Bekijk

Product information

български (BG) (2.77 MB - PDF)

Bekijk

español (ES) (1.33 MB - PDF)

Bekijk

čeština (CS) (1.83 MB - PDF)

Bekijk

dansk (DA) (1.27 MB - PDF)

Bekijk

Deutsch (DE) (1.23 MB - PDF)

Bekijk

eesti (ET) (1.12 MB - PDF)

Bekijk

ελληνικά (EL) (2.57 MB - PDF)

Bekijk

français (FR) (1.19 MB - PDF)

Bekijk

italiano (IT) (1.33 MB - PDF)

Bekijk

latviešu (LV) (2.07 MB - PDF)

Bekijk

lietuvių (LT) (1.57 MB - PDF)

Bekijk

magyar (HU) (1.75 MB - PDF)

Bekijk

Malti (MT) (1.84 MB - PDF)

Bekijk

Nederlands (NL) (2.12 MB - PDF)

Bekijk

polski (PL) (2.02 MB - PDF)

Bekijk

português (PT) (1.39 MB - PDF)

Bekijk

română (RO) (1.51 MB - PDF)

Bekijk

slovenčina (SK) (1.98 MB - PDF)

Bekijk

slovenščina (SL) (1.88 MB - PDF)

Bekijk

suomi (FI) (1.15 MB - PDF)

Bekijk

svenska (SV) (1.28 MB - PDF)

Bekijk
Latest procedure affecting product information:A20/0029
26/07/2011
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (522.48 kB - PDF)

Bekijk

español (ES) (436.31 kB - PDF)

Bekijk

čeština (CS) (475.2 kB - PDF)

Bekijk

dansk (DA) (436.62 kB - PDF)

Bekijk

Deutsch (DE) (435.54 kB - PDF)

Bekijk

eesti (ET) (436.51 kB - PDF)

Bekijk

ελληνικά (EL) (518.76 kB - PDF)

Bekijk

français (FR) (436.15 kB - PDF)

Bekijk

italiano (IT) (435.76 kB - PDF)

Bekijk

latviešu (LV) (511.76 kB - PDF)

Bekijk

lietuvių (LT) (504.68 kB - PDF)

Bekijk

magyar (HU) (550.99 kB - PDF)

Bekijk

Nederlands (NL) (429.54 kB - PDF)

Bekijk

polski (PL) (476.63 kB - PDF)

Bekijk

português (PT) (436.67 kB - PDF)

Bekijk

română (RO) (498.13 kB - PDF)

Bekijk

slovenčina (SK) (474.6 kB - PDF)

Bekijk

slovenščina (SL) (473.16 kB - PDF)

Bekijk

suomi (FI) (435.82 kB - PDF)

Bekijk

svenska (SV) (436.71 kB - PDF)

Bekijk

Product details

Name of medicine
Avaglim
Active substance
  • rosiglitazone
  • glimepiride
International non-proprietary name (INN) or common name
  • rosiglitazone
  • glimepiride
Therapeutic area (MeSH)
Diabetes Mellitus, Type 2
Anatomical therapeutic chemical (ATC) code
A10BD04

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

AVAGLIM is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control on optimal dosage of sulphonylurea monotherapy, and for whom metformin is inappropriate because of contraindication or intolerance.

Authorisation details

EMA product number
EMEA/H/C/000675
Marketing authorisation holder
SmithKline Beecham Ltd

980 Great West Road
Brentford
Middlesex
TW8 9GS
United Kingdom

Marketing authorisation issued
27/06/2006
Revision
11

Assessment history

This page was last updated on

Share this page